Inquis Medical Raises $75M Series C to Expand AVENTUS Thrombectomy Adoption

Menlo Park, CA, January 12, 2026 (Business Wire) -- Inquis Medical closed a $75 million Series C financing from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation pipeline. The raise follows a pivotal year in which the company transitioned to a commercial-stage organization, expanded regulatory clearance for pulmonary embolism, and published positive pivotal trial data demonstrating effective clot removal with minimized blood loss and no device-related adverse events. Management said the capital will support scaling commercial adoption across the venous thromboembolism market while continuing product innovation.

Read full article here.